Fiorenzo Villani Purchases 4,265 Shares of Portage Biotech (NASDAQ:ALP) Stock

Portage Biotech Inc. (NASDAQ:ALP) insider Fiorenzo Villani bought 4,265 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were purchased at an average price of $4.05 per share, for a total transaction of $17,273.25. Following the completion of the transaction, the insider owned 38,886 shares of the company’s stock, valued at $157,488.30. This represents a 12.32% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Fiorenzo Villani also recently made the following trade(s):

• On Tuesday, September 15th, Fiorenzo Villani purchased 7,900 shares of Portage Biotech stock. The stock was purchased at an average price of $4.15 per share, with a total value of $32,785.00.
• On Tuesday, September 15th, Fiorenzo Villani acquired 10,382 shares of Portage Biotech stock. The stock was acquired at an average price of $4.07 per share, for a total transaction of $42,254.74.
• On Monday, September 14th, Fiorenzo Villani bought 2,000 shares of Portage Biotech stock. The shares were acquired at an average price of $4.16 per share, with a total value of $8,320.00.
• On Wednesday, September 9th, Fiorenzo Villani bought 7,000 shares of Portage Biotech stock. The shares were acquired at an average price of $5.07 per share, with a total value of $35,490.00.

Portage Biotech Stock Up 3.3%

Shares of NASDAQ ALP opened at $4.65 on Friday. Portage Biotech Inc. has a 12-month low of $3.20 and a 12-month high of $690.00. The company has a market capitalization of $7.21 million, a PE ratio of -0.01 and a beta of 0.54. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.31 and a quick ratio of 0.31. The firm’s 50-day moving average is $9.54 and its two-hundred day moving average is $14.32.

Portage Biotech (NASDAQ:ALP) last issued its quarterly earnings data on Thursday, July 16th. The company reported $23.75 earnings per share for the quarter. The business had revenue of $0.05 million for the quarter. Equities analysts anticipate that Portage Biotech Inc. will post -14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on ALP shares. Wall Street Zen raised Portage Biotech to a “hold” rating in a research note on Saturday, September 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Portage Biotech in a report on Friday, July 24th. HC Wainwright began coverage on shares of Portage Biotech in a research note on Monday, August 17th. They set a “neutral” rating and a $12.50 price target on the stock. Finally, Zacks Research upgraded shares of Portage Biotech to a “hold” rating in a report on Tuesday, August 18th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $12.50.

About Portage Biotech

Portage Biotech Inc is a clinical-stage biotechnology company focused on developing immuno-oncology treatments designed to stimulate the immune system to target and eliminate cancer cells. Its research has centered on therapies involving invariant natural killer T (iNKT) cells, a specialized immune-cell population that may help generate targeted antitumor responses.

The company’s pipeline has included investigational therapies intended for use in solid tumors, including approaches that combine immune-cell activation with mechanisms designed to improve the tumor microenvironment and enhance treatment response.